
Pipeline Information
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-3245 (BRAF inhibitor)
Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)
Pamiparib (PARP 1/2 inhibitor)
Pamiparib + Radiotherapy and/or Temozolomide
Pamiparib + Temozolomide
Tislelizumab (anti-PD-1)
Tislelizumab + BGB-A333 (anti-PD-L1)
Tislelizumab + BGB-A425 (anti-TIM-3)
Tislelizumab + BGB-A445 (anti-OX40)
Tislelizumab + Ociperlimab (anti-TIGIT)
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)
Tislelizumab + BGB-15025 (HPK1 inhibitor)
Tislelizumab + Chemoradiotherapy
Tislelizumab + Chemotherapy
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy
Tislelizumab + Lenvatinib
Tislelizumab + Sitravatinib (multikinase inhibitor)
Zanidatamab (anti-HER2 bispecific antibody)
Zanidatamab + Chemotherapy +/- Tislelizumab
BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab (anti-PD-1)
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)
BGB-11417 (Bcl-2 inhibitor) monotherapy
ME-401 (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*
Zanubrutinib
Zanubrutinib + Lenalidomide +/- Rituximab
Zanubrutinib + Obinutuzumab
Zanubrutinib + Rituximab
Zanubrutinib + Tislelizumab
Zanubrutinib +/- Venetoclax†
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action